Allogeneic bone marrow-derived mesenchymal stem cell therapy (NIAID/ITN)

同种异体骨髓间充质干细胞疗法

Report date: 2023/01/12 15:28:54

Base Information

Drug NameAllogeneic bone marrow-derived mesenchymal stem cell therapy (NIAID/ITN)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsRejection of renal transplantation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)Immune Tolerance Network
China Registration ClassN/A

Develop Information

Active CompaniesImmune Tolerance NetworkNational Institute Of Allergy And Infectious Diseases (Niaid)
Inactive CompaniesN/A
Active IndicationsRejection of renal transplantation
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A